Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-10-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartcellmetastaticdose offirst dose
  Phrases that lowered it: safety ofinvestigatorpatientstumorsuln
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 5.1% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 125 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 14.9% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 486 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports marked serious: 80.4% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904 · started 2022 · scored riskier than 71% of active trials terminated
• Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 NCT02860936 · started 2015 · scored riskier than 60% of active trials completed
• Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) NCT04267120 · started 2020 · scored riskier than 85% of active trials terminated
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors NCT02501096 · started 2015 · scored riskier than 71% of active trials completed
• A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies NCT03321630 · started 2017 · scored riskier than 89% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.